Article Text

other Versions

PDF
Randomised controlled trial
The combination of phentermine and topiramate is an effective adjunct to diet and lifestyle modification for weight loss and measures of comorbidity in overweight or obese adults with additional metabolic risk factors
  1. Amanda G Powell1,
  2. Caroline M Apovian1,
  3. Louis J Aronne2
  1. 1Medicine, Boston University, Boston, Massachusetts, USA
  2. 2Weill-Cornell, Cornell University, New York, USA
  1. Correspondence to: Louis J Aronne
    Weill-Cornell, Cornell University, 1165 York Avenue, New York, NY 10065, USA; ljaronne{at}med.cornell.edu

Statistics from Altmetric.com

Commentary on: OpenUrlCrossRefPubMed

Context

Obesity is a growing epidemic with multiple associated comorbidities including type 2 diabetes, hypertension and hyperlipidaemia. Multiple studies have shown that weight loss can improve these obesity RR factors. But weight loss is difficult. There is an urgent need for new and more efficacious pharmacological treatments to help curtail this growing epidemic. There have been previous studies looking at the use of phentermine and topiramate as single agents for weight loss. In the CONQUER trial, Gadde and colleagues have asked whether a combination of these two agents could provide a more effective treatment option for obesity with fewer side effects.

Methods

The CONQUER trial is a randomised controlled trial to assess the effects of two different doses of the combination of controlled-release (CR) phentermine plus topiramate versus placebo on weight loss. The multicentred study enrolled 2487 patients with a body mass index between 27 and 45 kg/m …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.